GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Current Deferred Revenue

Intra-Cellular Therapies (STU:23I) Current Deferred Revenue : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Intra-Cellular Therapies's current deferred revenue for the quarter that ended in Mar. 2024 was €0.0 Mil.

Intra-Cellular Therapies Current Deferred Revenue Historical Data

The historical data trend for Intra-Cellular Therapies's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Current Deferred Revenue Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intra-Cellular Therapies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Intra-Cellular Therapies Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (STU:23I) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Current Deferred Revenue
Comparable Companies
ELAN LNTH ALKS PRGO PBH ALVO AMPH DVAX CTLT IRWD ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
ITCI:USA ITCI:Mexico 23I:Germany
Address
430 East 29th Street, New York, NY, USA, 10016
Website
https://www.intracellulartherapies.com
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (STU:23I) Headlines

No Headlines